Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q1 Loss Up on Slightly Higher Expenses

Premium

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported a slight increase in its first-quarter net loss on modestly higher costs.

For the three-month period ended March 31, 2014, RXi's net loss was $2.3 million, up from $2.1 million in the year-ago quarter. The first-quarter 2013 loss does not include the impact of a one-time charge of $12.3 million related to the company's acquisition of Opko Health's RNAi assets.

Research and development spending in the quarter was $1.5 million, essentially flat with the first quarter a year earlier, excluding the one-time Opko charge. Meantime, general and administrative costs rose to $800,000 from $700,000.

At the end of the first quarter, RXi had cash and cash equivalents totaling $12 million.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.